The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C  by Liu, Chen-Hua et al.
The ratio of aminotransferase to platelets is a useful
index for predicting hepatic fibrosis in hemodialysis
patients with chronic hepatitis C
Chen-Hua Liu1,2,3, Cheng-Chao Liang4, Chun-Jen Liu1,2,3, Shih-Jer Hsu5, Jou-Wei Lin5, Shih-I Chen5,
Peir-Haur Hung6, Hung-Bin Tsai7, Ming-Yang Lai1,2,3, Pei-Jer Chen1,2,3,8, Jun-Herng Chen9,
Ding-Shinn Chen1 and Jia-Horng Kao1,2,3
1Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei,
Taiwan; 2Hepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei,
Taiwan; 3Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University
Hospital, Taipei, Taiwan; 4Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan; 5Department of Internal
Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan; 6Department of Internal Medicine, Chiayi Christian
Hospital, Chia-Yi, Taiwan; 7Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Chia-Yi, Taiwan; 8Department of
Medical Research, National Taiwan University Hospital, Taipei, Taiwan and 9Department of Pathology, National Taiwan University
Hospital, Yun-Lin Branch, Douliou, Taiwan
Percutaneous liver biopsy is the gold standard for staging
hepatic fibrosis of hemodialysis patients with chronic
hepatitis C before renal transplantation or antiviral therapy.
Concerns exist, however, about serious post-biopsy
complications. To evaluate a more simple approach using
standard laboratory tests to predict hepatic fibrosis and its
evolution, we studied 279 consecutive hemodialysis patients
with chronic hepatitis C and a baseline biopsy. Among them,
175 receiving antiviral therapy underwent follow-up biopsy
to evaluate the histological evolution of fibrosis. Multivariate
analysis of routine laboratory tests at baseline showed the
aspartate aminotransferase-to-platelet ratio index was an
independent predictor of significant hepatic fibrosis. The
areas under curves of this ratio to predict fibrosis stages
F2-4 were 0.83 and 0.71 in the baseline and follow-up sets;
and 0.75 and 0.80 respectively, for patients with sustained or
non-sustained virological response groups in the follow-up
sets. By a judicious setting of cut-off levels for the baseline
and non-sustained groups, and the sustained virological
response group, almost half and 60 percent of the baseline
and follow-up sets could be correctly diagnosed without
biopsy. Our study found the aminotransferase-to-platelet
ratio index is accurate and reproducible for assessing
hepatic fibrosis in hemodialysis patients with chronic
hepatitis C. Applying this simple index could decrease the
need of percutaneous liver biopsy in this clinical setting.
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Chronic hepatitis C (CHC) remains common in hemodia-
lysis (HD) patients with the estimated prevalence of 3–80%.1
Although these patients usually present with mildly elevated
serum aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels, several studies indicated that
they harbored high risks of liver-related morbidity and mor-
tality at both maintenance dialysis and post-renal transplan-
tation stages.2–4
Currently, percutaneous liver biopsy (PLB) is the gold
standard for staging hepatic fibrosis.5 Evaluating the
severity of liver histology for HD patients with CHC can
help clinicians determine the eligibility of renal transplanta-
tion, the long-term prognosis, and the necessity of initiating
interferon-based therapy.1,6–10 However, PLB is costly and
may cause serious hemorrhage in HD patients.11–15 Further-
more, sampling and interpretation variability is often
encountered.16,17 A noninvasive test to evaluate the hepatic
fibrosis is thus required, particularly in monitoring HD
patients with CHC over time.
Noninvasive tests using routine biochemical indices,
including AST-to-platelet ratio index (APRI) or Forns’ score,
have shown to be useful in evaluating the severity of hepatic
fibrosis in ordinary CHC patients.18–20 However, the value of
using routine biochemical indices to predict the severity of
hepatic fibrosis in HD patients with CHC remains disputed
and deserves further validation.15,21,22 Furthermore, data
to predict the evolution of hepatic fibrosis by biochemical
indices in these patients are still lacking. We therefore
aimed to confirm and validate the usefulness of routine
biochemical indices in predicting the severity of hepatic
fibrosis in HD patients with CHC before renal transplantation
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or antiviral therapy, and evaluate its role in correlating with
the evolution of hepatic fibrosis in those with paired liver
biopsies.
RESULTS
Patient characteristics
Of the 292 patients screened, 13 were excluded from the
study because of hepatitis B virus co-infection in seven,
hepatocellular carcinoma in two, decompensated cirrhosis in
two, and declining PLB in two. The clinical characteristics of
the remaining 279 eligible patients are summarized in Table 1.
The mean length of the biopsy samples was 18.1±1.4 mm
without fragmentation. Of the 279 eligible patients with
baseline PLB, 101 (36.2%) had significant hepatic fibrosis
(XF2). Two hundred forty-two patients (86.7%) received
6 to 12 months of interferon-based therapy, and the
overall sustained virologic response (SVR) rate was 53.2%.
Of the 192 patients who completed follow-up after the
discontinuation of antiviral therapy, 175 (91.1%) received
follow-up PLB to evaluate the evolution of hepatic fibrosis
and 58 of them (33.1%) had significant hepatic fibrosis
(XF2). Furthermore, the proportion of significant hepatic
fibrosis at follow-up PLB did not statistically differ in patients
with SVR than those without SVR (32.2% versus 34.1%,
P¼ 0.79). The complication rates of the 454 liver biopsies
included local pain at the biopsy puncture site in 88 (19.4%),
shoulder soreness in 52 (11.5%), biopsy puncture site oozing
in 60 (13.2%), intrahepatic hematoma in 6 (1.3%) and
hemoperitoneum in 1 (0.2%).
Prediction factors for significant hepatic fibrosis
Table 2 shows the univariate and multivariate analyses of
various baseline factors to predict HD patients with CHC
harboring significant hepatic fibrosis. In univariate analysis,
age, platelet count, AST, total bilirubin, g-GT, and APRI were
associated with patients with significant hepatic fibrosis.
When these factors were put in multivariate analysis,
APRI was the only independent factor predicting patients
with significant hepatic fibrosis (OR: 1.08, CI: 1.03–1.13,
P¼ 0.003).
Diagnostic accuracy of APRI to predict significant
hepatic fibrosis
By multivariate analysis, APRI was considered useful to
predict HD patients with CHC presenting significant hepatic
fibrosis. ROC curve was constructed to evaluate the overall
diagnostic accuracy. Furthermore, we also evaluated the
reproducibility of APRI for the 175 patients (62.7%) who
received follow-up PLB after the discontinuation of anti-viral
therapy. The areas under curves (AUCs) to predict significant
hepatic fibrosis for patients undergoing baseline and
follow-up PLB were 0.83 (95% CI 0.78–0.88) and 0.71 (95%
CI 0.65–0.77), respectively (Figures 1a and b). We further
evaluated the differences of the diagnostic accuracy of APRI
in predicting significant hepatic fibrosis in patients with SVR
or non-SVR, and the AUCs for SVR and non-SVR groups
were 0.75 (95% CI 0.69–0.81) and 0.80 (95% CI 0.69–0.91),
respectively (Figures 1c and d).
Selective cut-off levels of APRI to predict significant
hepatic fibrosis
Table 3 shows the diagnostic accuracy to predict significant
hepatic fibrosis in both baseline and follow-up PLBs by
different cut-off levels. When we chose o0.40 and X0.80 to
predict the absence and presence of significant hepatic
fibrosis for patients with baseline PLB, 84.4% (136 of 161)
patients with APRI tested within this range could be correctly
diagnosed, and 48.7% (136 of 279) patients could avoid
invasive PLB. When we chose o0.30 and X0.60, and
chose o0.40 and X0.80 to predict the absence and presence
Table 1 | Baseline characteristics of hemodialysis patients
with chronic hepatitis C
Characteristics
HD patients with
CHC (n=279)
Age (years) 47.4±9.8
Male gender, n (%) 166 (59.5)
BMI (kg/m2) 23.5±3.4
Hemoglobin (g/l) 11.7±1.8
White blood cell count ( 109/l) 6.4±1.8
Platelet count ( 109/l) 194±58
Prothrombin time (INR) 0.94±0.21
Albumin (g/dl) 4.1±0.3
Bilirubin total (mg/dl) 0.4±0.4
AST (/ULN) 1.0±0.9
ALT (/ULN) 1.4±1.3
ALP (/ULN) 1.1±0.7
g-GT (/ULN) 2.9±1.6
Creatinine (mg/dl) 10.0±3.2
HCV RNA, log10 (IU/ml) 5.7±0.9
HCV genotype, n (%)
1a/1b 179 (64.2)
2a/2b 98 (35.1)
6 2 (0.7)
Indications for liver biopsy, n (%)
Before renal transplantation 37 (13.3)
Before anti-viral therapy 242 (86.7)
Standard IFN 32
Pegylated IFN 107
Pegylated IFN plus RBV 103
Length of biopsy samples (mm) 18.1±1.4
Fibrosis score (METAVIR), n (%)
F0 82 (29.4)
F1 96 (34.4)
F2 64 (22.9)
F3 25 (9.0)
F4 12 (4.3)
Overall SVR rate after antiviral therapy, n (%)a 102 (53.2)
Patients with follow-up liver biopsy, n (%)b 175 (62.7)
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; BMI, body mass index; CHC, chronic hepatitis C; HCV,
hepatitis C virus; HD, hemodialysis; IFN, interferon; INR, international normalized
ratio; IU, international unit; RBV, ribavirin; SVR, sustained virological response; ULN,
upper limit of normal; g-GT, g-glutamyl transpeptiase.
aBy intention-to-treat (ITT) analysis; data from the 192 patients with known end point,
and the remaining 50 patients were on treatment or on post-treatment follow-up.
b17 of the 192 patients (8.9%) receiving anti-viral therapy with known end point
declined follow-up percutaneous liver biopsy.
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of significant hepatic fibrosis for patients with follow-up PLB,
76.9% (90 of 117) and 74.8% (104 of 139) patients with APRI
tested within this range could be correctly diagnosed, and
51.4% (90 of 175) and 59.4% (104 of 175) patients could
avoid invasive PLB, respectively. Because the two different
cut-off levels showed equivocal diagnostic value for follow-up
Table 2 | Univariate and multivariate analyses with Wald tests of baseline factors in predicting patients with significant hepatic
fibrosis (XF2)
Univariate analysis Multivariate analysisa
Variables
Patients with significant
hepatic fibrosis (n=101)
Patients without significant
hepatic fibrosis (n=178) P-value s.e. OR (95% CI) P-value
Age (years) 49.2±8.8 46.3±10.2 0.02 0.02 1.01 (0.97–1.04) 0.59
Gender (male, %) 63 57 0.32 — — —
BMI (kg/m2) 23.8±3.4 23.4±3.5 0.40 — — —
Hemoglobin (g/l) 11.7±1.4 11.6±1.0 0.66 — — —
White blood cell count ( 109/l) 6.5±1.8 6.4±1.9 0.67 — — —
Platelet count ( 109/l) 174±62 205±53 o0.001 0.003 0.98 (0.97–0.99) 0.95
Prothrombin time (INR) 0.95±0.09 0.95±0.25 0.33 — — —
Albumin (g/dl) 4.1±0.3 4.0±0.4 0.35 — — —
Bilirubin total (mg/dl) 0.4±0.2 0.4±0.1 0.01 1.02 3.29 (0.45–24.24) 0.28
AST (/ULN) 1.3±0.8 0.8±0.4 o0.001 0.39 12.54 (5.84–26.94) 0.31
ALT (/ULN) 1.6±1.3 1.3±1.3 0.15 — — —
ALP (/ULN) 1.1±0.7 1.0±0.7 0.17 — — —
g-GT (/ULN) 2.1±3.7 1.3±2.4 0.02 0.05 1.06 (0.96–1.18) 0.22
Creatinine (mg/dl) 10.3±3.3 9.8±3.1 0.19 — — —
APRIa 100b 78.8±43.8 41.5±18.4 o0.001 0.03 1.08 (1.03–1.13) 0.003
Abbreviations: CI, confidence interval; OR, odds ratio; s.e., standard error.
aFactors with a P-value o0.05 by univariate analysis entered into multivariate analysis.
bAspartate aminotransferase-to-platelet ratio index multiplied by 100 to facilitate multivariate regression analysis.
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Figure 1 |ROC curves of APRI in predicting HD patients with CHC presenting significant hepatic fibrosis (XF2).
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PLB, and the AUC in the follow-up set was inferior to the
AUC in the follow-up set either with SVR or without SVR
(Figures 1b vs c or d), we further analyzed the diagnostic
accuracy of APRI by patients with SVR or non-SVR
separately (Table 4). When we chose either o0.30 and
X0.60, or o0.40 and X0.80 to predict the absence and
presence of significant hepatic fibrosis for SVR or non-SVR
group, 81.7% (58 of 71) in the SVR group, and 80.7% (46 of
57) patients in the non-SVR group with APRI tested within
this range could be correctly diagnosed, and 64.4% (58 of 90)
and 54.1% (46 of 85) patients could avoid invasive PLB,
respectively. Therefore, if we stratified the cut-off levels by
patients with or without SVR, 59.4% (104 of 175) patients
could be correctly staged for hepatic fibrosis by using the
APRI alone, without performing PLB. Table 5 illustrates
the post-test probability of patients with significant hepatic
fibrosis on the basis of different age and APRI values
calculated from the logistic regression model: Logit
(PXF2)¼4.357 þ 0.054 (APRI 100)þ 0.017 (age).
DISCUSSION
The use of simple and non-invasive tests to evaluate the
severity of hepatic fibrosis in HD patients with CHC is
important, because the staging PLB potentially bears higher
risks of serious complications. A useful non-invasive tool to
evaluate the stage of hepatic fibrosis would be helpful,
particularly in monitoring the evolution of hepatic fibrosis
for these patients. Previous reports using various biochemical
indices to predict the hepatic fibrosis showed divergent
results probably due to small sample size or retrospective
study design.15,22 Recently, Schiavon et al.21 retrospectively
enrolled a sizable number of HD patients with CHC who
underwent PLB, with laboratory tests performed within
6 months from the date of biopsies. They found that APRI
could accurately predict the severity of hepatic fibrosis and
about 52% of the patients could be correctly diagnosed
without PLB. Despite APRI to predict hepatic fibrosis is
valuable to ordinary CHC patients, no studies have validated
the diagnostic accuracy of APRI in HD patients with CHC.
Table 3 | Selective cut-off values of APRI for sensitivity, specificity, positive predictive value, and negative predictive value to
predict significant hepatic fibrosis (XF2) in patients with baseline and follow-up percutaneous liver biopsies
Baseline (n=279) Follow-up (n=175)
Patients
tested n (%)
Actual
fibrosis n (%)
Patients
tested n (%)
Actual
fibrosis n (%)
APRI
All
(n=279)
XF2
(n=101)
oF2
(n=178)
Sen
(%)
Spe
(%)
PPV
(%)
NPV
(%)
All
(n=175)
XF2
(n=58)
oF2
(n=117)
Sen
(%)
Spe
(%)
PPV
(%)
NPV
(%)
o0.30 44 (16) 3 (3) 41 (23) 97 23 42 93 78 (45) 14 (24) 64 (55) 76 55 45 82
X0.30 235 (84) 98 (97) 137 (77) 97 (55) 44 (76) 53 (45)
o0.40 107 (38) 16 (16) 91 (51) 84 51 49 85 114 (65) 29 (50) 85 (73) 50 73 48 75
X0.40 172 (62) 85 (84) 87 (49) 61 (35) 29 (50) 32 (27)
o0.60 199 (71) 39 (39) 160 (90) 61 90 78 80 136 (78) 32 (55) 104 (89) 45 89 67 76
X0.60 80 (29) 62 (61) 18 (10) 39 (22) 26 (45) 13 (11)
o0.80 225 (81) 56 (55) 169 (95) 45 95 83 75 150 (86) 39 (67) 111 (95) 33 95 76 74
X0.80 54 (19) 45 (45) 9 (5) 25 (14) 19 (33) 6 (5)
o0.95 240 (86) 69 (68) 171 (96) 32 96 82 71 165 (94) 50 (86) 115 (98) 14 98 80 70
X0.95 39 (14) 32 (32) 7 (4) 10 (2) 8 (14) 2 (2)
Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; NPV, negative predictive value; PPV, positive predictive value; Sen, sensitivity; Spe, specificity.
Table 4 | Selective cut-off values of APRI for sensitivity, specificity, positive predictive value, and negative predictive value to
predict significant hepatic fibrosis (XF2) in patients with and without sustained virological response
With SVR (n=90) Without SVR (n=85)
Patients
tested n (%)
Actual
fibrosis n (%)
Patients
tested n (%)
Actual
fibrosis n (%)
APRI
All
(n=90)
XF2
(n=29)
oF2
(n=61)
Sen
(%)
Spe
(%)
PPV
(%)
NPV
(%)
All
(n=85)
XF2
(n=29)
oF2
(n=56)
Sen
(%)
Spe
(%)
PPV
(%)
NPV
(%)
o0.30 69 (76) 13 (45) 56 (90) 55 90 76 81 9 (11) 1 (3) 8 (12) 97 14 37 89
X0.30 21 (24) 16 (55) 5 (10) 76 (89) 28 (97) 48 (88)
o0.40 82 (92) 24 (83) 58 (95) 17 95 63 71 32 (38) 5 (17) 27 (48) 83 48 45 84
X0.40 8 (8) 5 (17) 3 (5) 53 (62) 24 (83) 29 (52)
o0.60 87 (97) 26 (90) 61 (100) 10 100 100 70 48 (56) 6 (21) 43 (77) 79 77 62 90
X0.60 3 (3) 3 (10) 0 (0) 37 (44) 23 (79) 13 (23)
o0.80 90 (100) 29 (100) 61 (100) 0 100 —a 68 60 (71) 10 (34) 50 (89) 65 89 76 83
X0.80 0 (0) 0 (0) 0 (0) 25 (29) 19 (66) 6 (11)
o0.95 90 (100) 29 (100) 61 (100) 0 100 —a 68 75 (88) 21 (72) 54 (96) 28 96 80 72
X0.95 0 (0) 0 (0) 0 (0) 10 (12) 8 (28) 2 (4)
Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; SVR, sustained virological response.
aNot applicable because no patients in SVR group had APRIX0.80 at follow-up percutaneous liver biopsy.
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Our results are in line with previous studies in both HD and
ordinary CHC patients that AST levels and PLT count were
independently associated with patients with significant
hepatic fibrosis.21,22 Furthermore, AUC of our patients
(0.83) with baseline PLB is similar to that of Schiavon’s ones
(0.80).21 Although the sensitivity, specificity, and NPV to
predict significant hepatic fibrosis were similar in our and
Schiavon’s studies when the cut-off levels set at o0.40 and
X0.95, the PPV differed much between them. This
discrepancy between Schiavon’s study and ours could be
reasoned by the following: (1) differences in the prevalence of
the enrolled patient with significant hepatic fibrosis (23.7
versus 36.2%); (2) differences in the time interval between
the PLB and the routine laboratory tests (within 6 months
versus 2 weeks); (3) differences in the nature of study
design (retrospective chart review versus prospective design );
(4) differences in the mean length of biopsy specimen
(13.7±4.8 mm versus 18.1±1.4 mm), affecting the biopsy
interpretation. It is generally believed that the different
prevalence of significant fibrosis is a more probable cause for
these discrepancies. Shaheen et al.19 conducted a systemic
review of APRI for the prediction of hepatic fibrosis in
ordinary CHC patients, and they concluded the major
strength of APRI is to exclude patients with significant
hepatic fibrosis, especially in the lower prevalence setting.
Because the proportion of CHC patients receiving HD with
significant hepatic fibrosis was lower than those with elevated
ALT levels and similar to those with persistently normal
ALT levels, setting APRI o0.40 was reliable to exclude HD
patients with significant hepatic fibrosis.15,21,23,24
With the high prevalence of HCV infection in HD patients
and the improving responses to interferon-based therapies
for chronically infected patients, monitoring the evolution of
hepatic fibrosis after treatment is also important. However,
few studies evaluated the value of APRI to predict the severity
of hepatic fibrosis in patients with follow-up PLB. Our study
also included 175 HD CHC patients with follow-up PLB after
interferon-based therapy. Nevertheless, the AUC of APRI in
the follow-up set to predict significant hepatic fibrosis was
inferior to that in the baseline set (0.71 versus 0.83), and the
predictive value by applying different cut-off levels were only
modest. We speculated that the best cut-off levels of APRI for
the SVR patients at baseline and follow-up may differ,
probably because of the rapid decrease of AST levels after
the treatment, whereas the regression of fibrosis may not
be evident. In contrast, those for the non-SVR patients at
baseline and follow-up were more likely to remain un-
changed. When the diagnostic accuracy of APRI to predict
significant hepatic fibrosis for patients with SVR and non-
SVR were independently analyzed, both the AUCs were
higher than that with combined analysis. By using different
cut-off levels of APRI for the SVR (o0.30 and X0.60) and
non-SVR (o0.40 and X0.80) patients, more patients tested
for APRI fell within these ranges, and thus can be correctly
diagnosed without performing PLB. Of particular note was
the comparable AUC, sensitivity, specificity, PPV and NPV of
APRI to predict significant hepatic fibrosis between baseline
patients and follow-up patients without SVR, confirming the
reproducibility of APRI to predict the severity of hepatic
fibrosis in HD patients with CHC.
Although APRI is considered useful for the prediction
of severity of hepatic fibrosis in this prospective cohort,
limitations still exist. First, our study is based on the
assumption that PLB, which takes only 1/50,000 the size of
the liver, is the gold standard for the assessment of hepatic
fibrosis. Although sampling and interpretation of variations
might occur, our study took strict sampling and interpreta-
tion procedures with the mean length of the biopsy samples
being 18.1 mm without tissue fragmentation, and with one
experienced pathologist to review all the samples to minimize
such errors. Second, about 42% of patients with APRI fell
between these 2 cut-off levels, leaving the severity of hepatic
fibrosis unclassified. Applying the post-test probability for
significant hepatic fibrosis on the basis of specific APRI value
can help clinicians determine whether a liver biopsy is
warranted. Third, the accuracy of APRI to predict cirrhosis
and its role to replace PLB for patients with cirrhosis cannot
be evaluated in this study due to its low prevalence (4.3%).
Fourth, the time interval between the baseline and the follow-
up PLB in patients receiving anti-viral therapy is 12–18
months, when the changes of hepatic fibrosis stages may not
be evident. Considering the slow regression of hepatic fibrosis
and the persistently normalized AST levels in patients with
SVR, the AUC of APRI to predict significant hepatic fibrosis
Table 5 | Post-test probability of significant hepatic fibrosis
(XF2) based on different age and APRI valuesa
Age
APRI
18–25
years
26–35
years
36–45
years
45–55
years
56–65
years
0.06–0.10 2.7b 3.2 3.8 4.4 5.2
0.11–0.15 3.6 4.1 4.9 5.7 6.7
0.16–0.20 4.6 5.3 6.3 7.3 8.6
0.21–0.25 6.0 6.9 8.1 9.4 11.0
0.26–0.30 7.7 8.8 10.3 12.0 13.9
0.31–0.35 9.8 11.3 13.1 15.1 17.4
0.36–0.40 12.5 14.2 16.5 18.9 21.7
0.41–0.45 15.7 17.9 20.5 23.4 26.6
0.46–0.50 19.7 22.2 25.3 28.6 32.2
0.51–0.55 24.3 27.2 30.7 34.4 38.3
0.56–0.60 29.6 32.8 36.7 40.7 44.9
0.61–0.65 35.5 39.1 43.2 47.4 51.6
0.66–0.70 41.9 45.6 49.9 54.1 58.3
0.71–0.75 48.6 52.4 56.6 60.7 64.7
0.76–0.80 55.3 59.0 63.1 66.9 70.6
0.81–0.85 61.8 65.4 69.1 72.6 75.9
0.86–0.90 68.0 71.2 74.6 77.6 80.5
0.91–0.95 73.5 76.4 79.3 82.0 84.4
0.96–1.00 78.4 80.9 83.4 85.6 87.6
1.01–1.05 82.7 84.7 86.8 88.6 90.2
1.06–1.10 86.2 87.9 89.6 91.1 92.4
1.11–1.15 89.1 90.5 91.9 93.1 94.1
1.16–1.20 91.5 92.6 93.7 94.6 95.4
aCalculated based on APRI and age included in the multivariate logistic regression
model: Logit (PXF2)=4.357+0.054 (APRI 100)+0.017 (age).
bPost-test probability was expressed in percentages.
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may be even higher if the time interval between the two
biopsies could be longer. In contrast, the diagnostic accuracy
of APRI to predict the long-term evolution of the hepatic
fibrosis in patients without SVR might be similar, considering
the consistency of AUCs for the baseline and follow-up sets.
Fifth, because the variability of AUC is related to the
prevalence of fibrosis stages, the AUCs in our study should be
adjusted by the population-based sampling in HD patients
with CHC.25 To the best of our knowledge, there was no
large-scaled study to evaluate the distribution of hepatic
fibrosis stages in this special group of patients for
standardization. On the other hand, our study consecutively
enrolled patients in each participating center, which may
reflect the naturally observed prevalence of different fibrosis
stages. Further large studies are awaited to define the severity
of hepatic fibrosis in these patients.
In conclusion, our data indicate that APRI is accurate and
reproducible to evaluate significant hepatic fibrosis in HD
patients with CHC before anti-viral therapy or renal trans-
plantation. Applying this simple index in our clinical practice
may reduce the need of staging PLB in this special clinical
setting. Further large studies are needed to confirm the role of
APRI in predicting the long-term evolution of hepatic fibrosis.
MATERIALS AND METHODS
Patients
From January 2005 to February 2009, a total of 292 consecutive HD
patients aged between 18 and 65 years with CHC who were
scheduled to receive renal transplantation or interferon-based
therapy were prospectively evaluated at four academic centers in
Taiwan. HD patients with CHC were defined as patients
with creatinine clearance of less than 10 milliliter per minutes per
1.73 square meters of body surface area who received maintenance
renal replacement therapy through vascular routes and harbored
persistent anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic,
Chicago, IL, USA) as well as HCV RNA (Cobas TaqMan HCV Test
v2.0, Roche Diagnostics GmbH, Mannheim, Germany) for more
than 6 months. Patients who received interferon-based therapy had
additional PLB 6 months after a course of 6 or 12 months of
treatment to evaluate histological evolution. Patients who were co-
infected with hepatitis B virus or human immunodeficiency virus,
had a history of heavy alcohol use, neoplastic diseases or other causes
of liver diseases, received immunosuppressive agents, had decom-
pensated cirrhosis (Child-Pugh class B or C), and were contra-
indicated for or declined PLB were excluded from this study. The
study conformed to the principles of the Helsinki Declaration and
was approved by the institutional review board of each participating
center. Each patient gave informed consent before enrollment.
Methods
Baseline demographic data were recorded for all patients. Hemo-
gram (including hemoglobin, white blood cell count, and platelet
count), serum biochemical data (including albumin, total bilirubin,
AST, ALT, alkaline phosphatase, g-glutamyl transpeptidase, and
serum creatinine), coagulation profiles, serological and virological
data were collected before PLBs. The hemogram and the routine
biochemistry were evaluated by the automated Sysmex XE-2100
hematology analyzer (Sysmex, Kobe, Japan) and the Toshiba TBA-
120 FR analyzer (Toshiba, Tokyo, Japan), respectively. All serological
data, including anti-HCV, HBsAg, anti-HBs, anti-HBc, and anti-
human immunodeficiency virus, were tested by the commercial kits.
HCV RNA (Cobas TaqMan HCV Test v2.0, Roche Diagnostics
GmbH) and HCV genotyping (Inno-LiPA HCV II, Innogenetics,
Ghent, Belgium) were tested for all patients at baseline and were
tested 6 months after the anti-viral therapy to evaluate the sustained
virological response (SVR). The AST-to-platelet ratio index (APRI)
was calculated as AST/upper limit of normal (ULN) 100/platelet
count (109/l).18
All patients eligible for the study underwent PLBs within 2 weeks
of the completion of blood tests. Ultrasound-guided liver biopsies
from the right hepatic lobe were performed using 16-G biopsy
needles (Temno Evolution, Allegiance, McGaw Park, IL, USA). The
sampling tissues were fixed with formalin, embedded with paraffin,
and stained with hematoxylin and eosin (H & E) and reticulin silver
(Masson trichome method). The hepatic fibrosis was staged by the
METAVIR scoring system, ranging from F0 to F4.26 Significant
hepatic fibrosis was defined as a fibrosis stage of XF2. All samples
were evaluated by one experienced pathologist who was unaware of
the clinical status of the study subjects.
Statistics
Statistical analyses were performed using Statistical Program
for Social Sciences (SPSS 12.0 for windows; SPSS, Chicago, Illinois,
USA). Patient characteristics were expressed as mean±s.d. and
percentage as appropriate. Two-sample t-test and w2 with Fisher’s
exact test for univariate analysis where appropriate and logistic
regression with Wald test for multivariate analysis of the baseline
hemogram and routine biochemistry were performed to find the
independent factors for patients with significant hepatic fibrosis
(XF2). The estimated sample size for multivariate regression model
was 260 based on the following assumptions: type I error¼ 0.05;
type II error¼ 0.10, estimated predictors¼ 3, and anticipated effect
size (f2)¼ 0.055, given a R2¼ 0.052. The diagnostic accuracy and
reproducibility of APRI for baseline and follow-up PLBs to predict
significant hepatic fibrosis were evaluated by the AUCs with
95% confidence intervals (CI), respectively. All statistical tests were
two-tailed and results were considered statistically significant when
a P-value was o0.05.
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